T he central nervous system (CNS) plays a critical role in the blood pressure (BP) regulation by modulating sympathetic drive to individual organs, leading to changes in blood volume, cardiac output, and vascular resistance.
T he central nervous system (CNS) plays a critical role in the blood pressure (BP) regulation by modulating sympathetic drive to individual organs, leading to changes in blood volume, cardiac output, and vascular resistance. 1 Within the forebrain, regions like the subfornical organ are capable of sensing changes in sodium and osmolality, which relay to the paraventricular nucleus (PVN) of the hypothalamus and further down to the rostral ventrolateral medulla. Altered plasticity of these neuronal networks can lead to an enhanced sympathetic drive and compromised vagal tone to various organs and trigger neurogenic hypertension.
The brain renin-angiotensin system plays an essential role in the development of neurogenic hypertension. Ang II (angiotensin II), the main peptide in this system, increases sympathetic outflow and BP, while decreasing baroreflex gain and vagal tone, by acting on brain AT 1 Rs (Ang II type 1 receptors). 2 In addition to the classic axis, compensatory mechanisms exist within the renin-angiotensin system. As a major component of the rescue mechanisms, ACE2 (angiotensin-converting enzyme type 2) plays a critical role in modulating the balance of reninangiotensin system, by transforming Ang II into Ang (1-7), a vasodilator peptide. 3 However, CNS expression and activity of ACE2 are found to be reduced during hypertension. 4, 5 We previously identified that ADAM17 (A disintegrin and metalloprotease 17)-mediated shedding is responsible for the reduction of brain ACE2 during salt-sensitive hypertension, and this process was then demonstrated to be mediated via neuronal AT 1 R. 6, 7 ADAM17 is a type of sheddase, which cleaves membrane-anchored proteins. 8 Upon brain renin-angiotensin system activation, ADAM17 can be upregulated and activated by AT 1 R-mediated signaling, such as reactive oxygen species/extracellular signal-regulated kinases and reactive oxygen species/p38mitogen-activated protein kinases, ultimately leading to a decrease in ACE2 activity. 7 We previously reported that targeting brain ADAM17 using siRNA was able to blunt hypertension, confirming its contribution in BP dysregulation. However, ADAM17 is robustly expressed in various cell types within the CNS, 7, 9 with a large array of target proteins that could support (eg, ACE2, TNF [tumor necrosis factor]-α, IL [interleukin]-6) or prevent (eg, TNF-α receptor, neuregulin 1) the development of hypertension. 10 Therefore, it is important to understand how activation of ADAM17 in specific neuronal populations could contribute to autonomic regulation.
The action of glutamate accounts for >90% of the excitatory synaptic connections in the vertebrate CNS. 11 We recently reported that optogenetic stimulation of the PVN glutamatergic neurons can lead to an immediate increase in BP, showing their critical role in regulating autonomic nervous system. 12 Glutamatergic activity is found to be enhanced in neurons projecting from PVN to brain stem or spinal cord in several hypertensive models, including spontaneous hypertensive rats, salt-sensitive hypertension, and Ang II-induced hypertension. [13] [14] [15] Moreover, activation of AT 1 R induces both decrease of GABAergic inhibition and increase of glutamatergic activity in neurons projecting from PVN to rostral ventrolateral medulla. [16] [17] [18] ACE2/Ang (1-7) signaling has been suggested to contribute to GABA release, 19, 20 in which case, ADAM17-mediated ACE2 shedding on GABAergic neurons could potentially promote sympathoexcitation. Previous work performed in the cortex, and hippocampus showed that glutamate induces ADAM17-mediated shedding of neuregulin 1, which is thought to modulate excitatory synapse maturation. 21 However, there is a lack of knowledge on the potential role of ADAM17, located on glutamatergic neurons, in autonomic regulation. In this study, we hypothesized that ADAM17 upregulation in glutamatergic preautonomic neurons would lead to enhanced sympathetic activity during deoxycorticosterone acetate (DOCA)-salt treatment. To test this hypothesis, we generated mice with ADAM17, or AT 1 R, selectively knocked down from these cells, and investigated the impact of this deletion on sympathoexcitation during the development of salt-sensitive hypertension.
Methods
A detailed Methods section is available in the online-only Data Supplement.
The data that support the findings of this study are available from the corresponding author on reasonable request.
Transgenic Mice and Animal Husbandry
Experiments were performed on adult male mice (14-16 weeks old). ADAM17 knockdown mice (mice with ADAM17 knockdown in glutamatergic neurons [A17G]), AT 1 R knockdown mice (mice with AT 1a R knockdown in glutamatergic neurons [AT1G]), and controls carrying 1 copy of Cre recombinase (heterozygous, Cre
) under the control of the vGluT2 (vesicular glutamate transporter 2) promoter ( Figure 1A ). All 3 strains have a C57BL/6J genetic background. All animals were housed in a temperature-and humidity-controlled facility under a 12-hour dark/light cycle, fed standard mouse chow (Envigo, Teklad) and water ad libitum. To test our hypothesis, conditional knockdown and control mice were subjected to salt-sensitive hypertension, while sympathetic drive to various end organs (ie, heart, vasculature, and spleen) was evaluated using molecular, cellular, and pharmacological approaches.
Statistics
Data are presented as means±SEM. Unless specified otherwise, data were analyzed by repeated measures ANOVA, or 2-way ANOVA, followed by Bonferroni post hoc test for multiple comparisons between means, when appropriate. Statistical analyses were performed using Prism5 (GraphPad Software). Differences were considered statistically significant at P <0.05.
Results

ADAM17 in Glutamatergic Neurons Mediates SaltSensitive Hypertension and Impaired Baroreflex Gain
To test our hypothesis, we generated 2 transgenic mouse models, in which ADAM17 (A17G) or AT 1 R (AT1G) were selectively knocked down from glutamatergic neurons, using Cre recombinase driven by the vGluT2 promoter. Cre-targeted glutamatergic neurons were visualized using a tdTomato reporter (Tomato + , Figure 1A and 1B). Using a fluorescence-activated cell sorting approach, Tomato + cells were collected from the forebrain of AT1G, A17G, and controls ( Figure 1C) . Validation of the gene knockdown was assessed by quantitative reverse transcription polymerase chain reaction, and significant reduction of AT 1a R mRNA in AT1G ( Figure 1D ) and ADAM17 mRNA in A17G ( Figure 1E ) was confirmed. Mice with ADAM17 or AT 1 R knockdown from glutamatergic neurons developed normally, and there was no significant difference in body, organs, or tissues weight compared with controls (Table S1 in the online-only Data Supplement). Basal renal sympathetic nerve activity ( Figure  S1A ) trended toward a reduction in both A17G and AT1G mice. Surprisingly, sympathetic nerve activity to the brown adipose tissue was found to be markedly higher in A17G mice ( Figure  S1B ), indicating that the impact of ADAM17 on neuronal activity is not homogenous throughout glutamatergic neurons.
Baseline BP showed no difference among A17G, AT1G, and control mice, suggesting that neither ADAM17 nor AT 1 R in glutamatergic neurons significantly contributes to the maintenance of BP in basal conditions (Figure 2A and 2B ). Similar to AT1G, daily BP recording during DOCA-salt treatment showed a significantly blunted hypertension in A17G mice (Figure 2A) , with a plateau shown as early as the end of the first week, when BP is still rising in controls. Despite this blunted hypertension, reflex bradycardia was similar among the 3 groups ( Figure 2C ). Further analysis ( Figure 2D ) showed that the baroreflex gain of DOCAsalt-treated mice ranged from improved in A17G to preserved in AT1G, while it was dramatically reduced in control mice.
ADAM17 in Glutamatergic Neurons Contributes to Cardiac and Vascular Sympathoexcitation
As expected, analysis of autonomic function in control mice showed a typical increase in both cardiac ( Figure 3A ) and vascular ( Figure 3B ) sympathetic activities, as well as a reduction of vagal tone ( Figure 3C ), which altogether contributed to the maintenance of hypertension during DOCA-salt treatment. Knockdown of ADAM17 in glutamatergic neurons did not induce any significant change in autonomic function at baseline. Similar to AT1G, the DOCA-salt-induced increase in sympathetic drive was prevented in A17G mice ( Figure 3A and 3B), as neither cardiac nor vascular sympathetic drives were increased after DOCA-salt treatment in these mice. Interestingly, cardiac vagal tone was still impaired by DOCA-salt challenge in A17G (*P<0.05 versus A17G sham, Figure 3C ).
To further confirm the contribution of ADAM17 activation to the increase of sympathetic outflow, cardiac function was evaluated via echocardiography in these mice. DOCA-salt treatment induced cardiac hypertrophy ( Figure S2A ) and early signs of heart failure in control mice, including decreased systolic function ( Figure 3D ) and enlarged left ventricle chamber size ( Figure S2B ). This hypertension-driven left ventricle hypertrophy is often considered as end-organ damage resulting from sympathetic activation. 22 The early signs of heart failure were completely prevented in A17G, confirming a normalized cardiac sympathetic drive in these mice. Hypertension-induced vascular hypertrophy was also attenuated in A17G mice ( †P<0.05 versus Control+DOCA-salt, Figure 3E ), as evidenced by the smaller media increase after DOCA-salt treatment. As a global index of sympathetic activity, urinary NE levels were measured at the end of DOCA-salt treatment. Although still elevated, compared with baseline, norepinephrine excretion was reduced by ≈50% in A17G mice post-DOCA-salt treatment ( Figure S2C ).
ADAM17 in Glutamatergic Neurons Mediates Peripheral Immune System Activation in SaltSensitive Hypertension
Sympathetic activation is thought to be an important drive for activation of the peripheral immune system, which in turn contributes to hypertension. Our data ( Figure 4A and 4B) show that 3 weeks of DOCA-salt treatment increases splenic sympathetic activity, as evidenced by tyrosine hydroxylase levels-a rate-limiting enzyme in the formation of norepinephrine-in a splenic region (white pulp) known for T-cell storage. Tyrosine hydroxylase expression in the spleen was dramatically elevated in DOCA-salt-treated control mice (**P<0.01 versus control sham), while it was significantly attenuated in mice lacking ADAM17 in glutamatergic neurons. DOCA-salt treatment is known to induce a significant reduction of splenic T cells (ie, CD3 expression), and this deployment of T cells seems to be critical for downstream infiltration of target organs and peripheral inflammation. 23, 24 Indeed, analysis of peripheral blood mononuclear cells, isolated from the whole blood, confirmed that specific inflammatory cell populations, including CD3 + and CD8 + T cells, were increased in the circulation of control mice after DOCA-salt challenge ( Figure 4C and 4D) . However, in A17G mice, DOCAsalt hypertension was not able to recruit CD3 + and CD8 + T cells to the circulation and they remained sequestered to the spleen.
ADAM17 Supports Ang II-Induced Neuronal Excitation in the PVN
ADAM17 is robustly expressed in glutamatergic PVN neurons ( Figure 5A ). To assess whether ADAM17 modulates neuronal activity, whole-cell patch-clamp recordings were performed on retrogradely labeled presympathetic glutamatergic PVN neurons ( Figure S3 ), which project to sympathetic ganglia that innervate the kidney. Figure S4D ). In contrast, in AT1G, only 1 out of 11 presympathetic PVN neurons depolarized after Ang II, confirming that this Ang II-induced response was mainly mediated by AT 1 R on glutamatergic neurons (*P<0.05, AT1G versus control). In A17G mice, only 3 out of 10 kidney-related PVN neurons depolarized after Ang II application, supporting a reduced excitability of glutamatergic neurons in the shortage of ADAM17. In addition, while it showed no difference in control neurons ( Figure  S4F ), the input resistance (R in ) was significantly lower in responder neurons of A17G, compared with their nonresponder counterparts ( Figure S4G ). This suggests that depolarization of A17G neurons might require more ion channels to open.
We assessed the expression of Gad67, a critical enzyme that catalyzes the formation of GABA, to possibly explain the blunted sympathoexcitation in A17G mice. As shown in Figure 5D , DOCA-salt treatment significantly reduced Gad67 mRNA level in the hypothalamus, implying an impaired GABAergic inhibitory activity in DOCA-salt hypertension. On the other hand, Gad67 expression was significantly higher in the hypothalamus of DOCA-salt-treated A17G mice, suggesting a negative impact of ADAM17 activation on GABAergic signaling. Meanwhile, mRNA levels for N-methyl-D-aspartate receptors (Grin1), AMPA receptors (GluR1), and GABAa receptors in the hypothalamus of A17G mice were unaffected compared with controls ( Figure S5A ). Assessment of ADAM17 presence in other neuronal populations and brain regions revealed its expression in GABAergic neurons within the median preoptic nucleus, PVN, and bed nucleus of the stria terminalis ( Figure  S5B ). As to the brain stem, ADAM17 is also distributed in glutamatergic neurons including the rostral ventrolateral medulla and nucleus of solitary tract ( Figure S5C and S5D) .
Finally, to clarify the paradoxical increase of vagal tone during hypertension in mice lacking AT 1 R on glutamatergic neurons ( Figure 3C ), we speculated that AT 2 R might be involved. In situ hybridization revealed that AT 2 R are also expressed on glutamatergic neurons within the PVN (Figure 5E ), possibly opposing the AT 1 R-mediated sympathoexcitation. Intracerebroventricular pretreatment with PD123319, a specific AT 2 R antagonist, completely abolished the enhanced cardiac vagal tone in DOCA-salt-treated AT1G mice ( Figure 5F ).
Discussion
Although ADAM17 was originally discovered as a key sheddase for cytokines release, with a wide spectrum of substrates, 8 our previous reports highlighted its important role, beyond inflammation, in the development of hypertension. 6, 7 We previously reported that during salt-sensitive hypertension, upregulation of ADAM17 takes place selectively in neurons, after activation of AT 1 R-mediated signaling pathways. 7 Here, we aimed at clarifying the contribution of neuronal ADAM17 to autonomic dysregulation in salt-sensitive hypertension.
Among the new findings of our study in mice lacking glutamatergic ADAM17 are (1) a preserved cardiovascular function (Figure 3) , (2) a blocked activation of the immune system (Figure 4) , and (3) persistence of an impaired vagal tone after DOCA-salt treatment. Specifically, these mice exhibited a blunted surge of sympathetic activity, which resulted in a lesser BP increase, reduced cardiac and vascular remodeling, and impaired deployment of T cells to target organs.
Recently, activation of splenic sympathetic nerves was shown to play an essential role in the development of peripheral inflammation and hypertension. 23 The spleen is mainly innervated by sympathetic nerve terminals, and splenic sympathetic nerve activity was found to be increased at the early phase of DOCA-salt treatment. 24 In mice with ADAM17 knockdown, DOCA-salt-induced increases in tyrosine hydroxylase expression and circulating T cells were effectively blocked, while their BP was still significantly higher than baseline, supporting a critical role of the sympathetic drive, rather than BP itself, in activating the peripheral immune system. Although global deletion of ADAM17 has been associated with impaired T-cell development and B-cell maturation, 25 persistence of ADAM17 activity outside of glutamatergic neurons is sufficient to maintain a normal physiological function, 8 so our observation is not related to developmental defects. According to our previous study, the activity of glutamatergic neurons, in regions like the PVN, is directly linked to autonomic regulation. 12 Indeed, photoactivation of these PVN glutamatergic neurons resulted in an immediate BP rise, while their destruction prevented the development of salt-sensitive hypertension. Therefore, we speculated that ADAM17 could take part in sympathoexcitation by modulating the excitability of these glutamatergic neurons. Our patch-clamp experiments confirmed this assumption as the proportion of depolarized cells, in response to Ang II, was reduced in kidney-projecting presympathetic glutamatergic neurons from ADAM17 knockdown mice. This supportive role of ADAM17 toward neuronal excitability of presympathetic glutamatergic neurons has not been reported previously but is consistent with an early study in ADAM17 global knockout mice where the authors speculated an increase in sympathetic activity to the brown adipose tissue, 26 a feature that was confirmed in our animals ( Figure S1B ). Interestingly, targeting ADAM17 did not produce the same effects as knocking down AT 1 R, with ADAM17 knockdown solely impacting sympathetic activity, while AT 1 R removal affected both sympathetic and parasympathetic outputs. Unlike AT1G and other models we reported previously, 6 ,7 cardiac vagal tone was not protected in DOCA-salt-treated A17G mice ( Figure 3C ), suggesting that activation of ADAM17 in glutamatergic neurons has no or fairly limited role in reducing vagal tone, but exclusively contributes to sympathetic output. Accordingly, Ang II/AT 1 R signaling is thought to impair vagal activity through an ADAM17-independent manner, which would support the reduction of baroreflex sensitivity observed in DOCA-salt-treated A17G mice ( Figure 2D ).
The involvement of brain AT 1 R in autonomic dysfunction has been well established in hypertension and heart failure. 2 Recent studies revealed a critical role of astrocyte AT 1 R in modulating the excitability of glutamatergic neurons and sympathoexcitation. 27, 28 In our study, strong evidence was provided to support the indispensable role of neuronal AT 1 R in Ang II-induced increase of glutamatergic activity and sympathoexcitation. In addition to in vivo data (Figures 2 and 3) , the Ang II-induced depolarization of glutamatergic neurons was found to be altered toward a nonresponding state or hyperpolarization, when AT 1 R was knocked down from those neurons ( Figure 5C ). Interestingly, DOCA-salt treatment produced an unexpected rise in vagal tone in AT1G mice ( Figure 3C ). This was demonstrated to be mediated by Ang II/AT 2 R signaling ( Figure 5E and 5F), which was unmasked when AT 1 R was knocked down. A similar role for AT 2 R has previously been reported in the brain stem. AT 1 R-mediated ADAM17 activation could support sympathoexcitation by decreasing the compensatory activity of ACE2 and increasing soluble TNF-α release. Indeed, ACE2 cleaves a phenylalanine from the carboxyl-terminal end of Ang II to form Ang (1-7) . 30 Through activation of an NO-mediated pathway, Ang (1-7) can significantly increase extracellular GABA level, without affecting glutamate release, 19 supporting its sympathoinhibitory role. However, the limited expression of ACE2 in PVN glutamatergic neurons ( Figure S6 ) suggests that glutamatergic ADAM17 might promote sympathoexcitation in a manner independent of ACE2 shedding. Unlike Ang (1-7), TNF-α plays a contributory role in glutamate-induced excitotoxicity, by inhibiting glutamate transporters on astrocytes both directly and indirectly. 31, 32 On one hand, TNF-α has direct effects on glutamate transmission, for example, stimulating the activity of NMDA receptors and upregulating the expression of synaptic AMPA receptors. 33, 34 On the other hand, acute application of TNF-α can induce a rapid and persistent decrease of inhibitory synaptic strength and downregulation of GABAa receptors. 35 Moreover, downstream of the ADAM17/ TNF-α pathway, activation of NF-κB is also found to be involved in the reduction of Gad67 and GABA in the PVN. [36] [37] [38] Despite the novel finding of ADAM17 selective contribution to sympathetic activity, there are some limitations to our study. First, in A17G mice, knockdown of ADAM17 is taking place in a vast network of glutamatergic neurons beyond those located in BP regulation-related nuclei (eg, PVN, nucleus of solitary tract, and rostral ventrolateral medulla) and the impact of this additional deletion is difficult to estimate. We recognize the possible contribution from sensory neurons, such as dorsal root ganglion neurons, which also express vGluT2. Although further work is needed to address those contributions, we consider our approach necessary to support further, more discrete, deletion in specific regions. 12 Second, although the percentage of Ang II-depolarized neurons was convincingly decreased in A17G mice, it did not reach statistical significance, due to the small sample size. However, we are confident that together our in vivo and ex vivo data support the important role of ADAM17 in sympathoexcitation.
Overall, our study suggests that activation of ADAM17 in glutamatergic neurons promotes the development of DOCA-salt hypertension by selectively increasing sympathetic outflow. As illustrated in our working model (Figure 6 ), activation of ADAM17 in glutamatergic neurons could increase the excitability of these neurons by releasing TNF-α and compromising the compensatory activity of ACE2. Although the mechanism still needs to be verified, ADAM17-mediated shedding in glutamatergic neurons seems to have a negative impact on GABAergic inhibitory activity in DOCA-salt hypertension. Altogether, ADAM17 activation supports the increase of glutamatergic neuronal excitability and sympathoexcitation, thus contributing to the development of neurogenic hypertension.
Perspectives
Using a salt-sensitive hypertension model, we uncovered that activation of ADAM17 in glutamatergic neurons leads to a selective increase of sympathetic output. ADAM17-mediated shedding is also taking place in the CNS of hypertensive patients. Exploring the role of ADAM17 in a specific population of brain cells might help us better understand drug-resistant hypertension and identify more effective treatments. Despite our findings, questions still remain. Further investigation is required to map the precise neuronal networks and mechanisms, through which ADAM17 participates to neuronal activation and sympathoexcitation. is controlled, due to the low excitability of presympathetic glutamatergic neurons. On deoxycorticosterone acetate (DOCA)-salt treatment, upregulated ADAM17 could increase the excitability of these neurons by releasing TNF (tumor necrosis factor)-α and compromising the compensatory activity of ACE2 (angiotensin-converting enzyme type 2), therefore, promoting sympathoexcitation. As result, cardiac output, vascular capacitance and resistance, and deployment of T cells from spleen are increased, inducing uncontrolled elevation of BP. With prolonged dysregulation of autonomic nervous system and BP, cardiovascular remodeling and peripheral inflammation are developed, further supporting the maintenance of hypertension. Ang II indicates angiotensin II; MasR, Mas receptor; GABA, gamma-aminobutyric acid; sACE2, soluble ACE2; sTNFα, soluble TNFα; SNA, sympathetic nerve activity.
